HOT STOCK BUY Heat Biologics, Inc. (HTBX)

Опубликовано: 01 Январь 1970
на канале: Maria Ioan Anton

Powered by Restream https://restream.io/

Heat Biologics, Inc., a biopharmaceutical company, focuses on developing immunotherapies to activate patient's immune system against cancer through T-cell activation and expansion. The company's T-cell activation platform, includes two variations for intradermal administration, such as immune pan-antigen cytotoxic therapy, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and combination pan-antigen cytotoxic therapy, a dual-acting immunotherapy, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. It is developing HS-110, which is in phase II clinical trials to treat patients with advanced non-small cell lung cancer. The company's preclinical stage products include HS-130 for the treatment of advanced solid tumors; PTX-35, a humanized affinity matured monoclonal antibody, which is a functional agonist of human TNFRSF25 signaling; and PTX-45, a human TL1A-Ig fusion protein that acts as an agonist of TNFRSF25 signaling. Heat Biologics, Inc. has collaboration with Waisman Biomanufacturing to manufacture COVID-19 Vaccine. The company was founded in 2008 and is headquartered in Morrisville, North Carolina.